Replies to post #7288 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: ATryn downstream processing

>Cambrex is doing that [fill/finish] job now for Atyrn<

It’s now done by Lonza, who bought the operation from Cambrex last year (#msg-22191984).

GTC has stated that they are seeking an alternate or second source to handle the larger volumes needed in acquired AT deficiencies. SIAL’s SAFC subsidiary is known to be one of the companies GTC has spoken to (#msg-23241644). Regards, Dew